Literature DB >> 24417217

A single-center, retrospective analysis evaluating the utilization of the opioid risk tool in opioid-treated cancer patients.

Joseph D Ma, John M Horton, Michael Hwang, Rabia S Atayee, Eric J Roeland.   

Abstract

The Opioid Risk Tool (ORT) is a screening tool used to assess risk of opioid misuse by stratifying aberrant drug-seeking behaviors and/or identifying known risk factors for drug abuse. The objectives of this study were to risk stratify opioid misuse in a cancer pain population and determine the most common patient risk factors associated with misuse utilizing the ORT. This was a retrospective analysis conducted at an academic comprehensive cancer center. Patients were referred by an oncologist or hematologist to an outpatient palliative care clinic. One-hundred and fourteen patients with cancer (n = 107) or sickle cell disease (n = 7) were evaluated from July 2012 to July 2013. During the clinical interview, patients responded to a clinician administered ORT. Based on the ORT score, patients were stratified into low, moderate, or high risk for opioid misuse. Sample size included 57 men and 57 women. Sixty-five, 21, and 28 patients were deemed low, moderate, and high risk based on the ORT, respectively. The most common risk factors for opioid misuse were a history of depression (women = 32; men = 22) and family history of alcohol abuse (women = 26; men = 22). There was no difference between men and women in the prevalence of depression (P = .17) or family history of alcohol abuse (P = .57). The least common risk factor was a personal history of prescription drug abuse (n = 1) in women and history of preadolescent sexual abuse in men (n = 0). Twenty-five percent (n = 28) of the sample population were deemed high risk based on the ORT. Screening of cancer patients in the palliative care setting suggests that risk factors for opioid misuse exist. Stratifying patients based on a routine screening tool may help identify cancer patients at risk for aberrant drug behaviors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24417217     DOI: 10.3109/15360288.2013.869647

Source DB:  PubMed          Journal:  J Pain Palliat Care Pharmacother        ISSN: 1536-0288


  7 in total

1.  Survey of Opioid Risk Tool Among Cancer Patients Receiving Opioid Analgesics.

Authors:  So Yeon Oh; Kwonoh Park; Su-Jin Koh; Jung Hun Kang; Myung Hee Chang; Kyung Hee Lee
Journal:  J Korean Med Sci       Date:  2022-06-13       Impact factor: 5.354

Review 2.  Chronic opioid therapy in long-term cancer survivors.

Authors:  A Carmona-Bayonas; P Jiménez-Fonseca; E Castañón; A Ramchandani-Vaswani; R Sánchez-Bayona; A Custodio; D Calvo-Temprano; J A Virizuela
Journal:  Clin Transl Oncol       Date:  2016-07-21       Impact factor: 3.405

Review 3.  Emerging Challenges to the Safe and Effective Use of Methadone for Cancer-Related Pain in Paediatric and Adult Patient Populations.

Authors:  Kyle P Edmonds; Ila M Saunders; Andrew Willeford; Toluwalase A Ajayi; Rabia S Atayee
Journal:  Drugs       Date:  2020-02       Impact factor: 9.546

Review 4.  A systematic review of assessment approaches to predict opioid misuse in people with cancer.

Authors:  Robyn Keall; Paul Keall; Carly Kiani; Tim Luckett; Richard McNeill; Melanie Lovell
Journal:  Support Care Cancer       Date:  2022-02-15       Impact factor: 3.359

5.  Patterns of analgesic adherence predict health care utilization among outpatients with cancer pain.

Authors:  Salimah H Meghani; George J Knafl
Journal:  Patient Prefer Adherence       Date:  2016-01-27       Impact factor: 2.711

Review 6.  Identifying and assessing the risk of opioid abuse in patients with cancer: an integrative review.

Authors:  Ashley-Nicole Carmichael; Laura Morgan; Egidio Del Fabbro
Journal:  Subst Abuse Rehabil       Date:  2016-06-02

Review 7.  Prevalence of Opioid Use Disorder among Patients with Cancer-Related Pain: A Systematic Review.

Authors:  Céline Preux; Marion Bertin; Andréa Tarot; Nicolas Authier; Nathalie Pinol; David Brugnon; Bruno Pereira; Virginie Guastella
Journal:  J Clin Med       Date:  2022-03-14       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.